HCA Healthcare, Inc. $HCA Stake Trimmed by Metis Global Partners LLC

Metis Global Partners LLC trimmed its position in HCA Healthcare, Inc. (NYSE:HCA) by 13.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 7,322 shares of the company’s stock after selling 1,172 shares during the period. Metis Global Partners LLC’s holdings in HCA Healthcare were worth $2,805,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in HCA. Wedbush Securities Inc. boosted its position in shares of HCA Healthcare by 71.9% in the second quarter. Wedbush Securities Inc. now owns 1,215 shares of the company’s stock worth $465,000 after buying an additional 508 shares during the period. Bryn Mawr Trust Advisors LLC acquired a new position in shares of HCA Healthcare in the 2nd quarter valued at about $234,000. Savant Capital LLC boosted its holdings in shares of HCA Healthcare by 15.5% during the second quarter. Savant Capital LLC now owns 3,302 shares of the company’s stock worth $1,265,000 after purchasing an additional 444 shares during the period. Soltis Investment Advisors LLC increased its stake in HCA Healthcare by 7.6% in the 2nd quarter. Soltis Investment Advisors LLC now owns 1,889 shares of the company’s stock valued at $724,000 after buying an additional 133 shares during the period. Finally, Spurstone Advisory Services LLC purchased a new position in shares of HCA Healthcare during the 2nd quarter valued at $454,000. 62.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total value of $1,843,990.68. Following the sale, the executive vice president owned 3,487 shares in the company, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. This represents a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HCA. Jefferies Financial Group boosted their target price on HCA Healthcare from $485.00 to $525.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. UBS Group raised their price objective on shares of HCA Healthcare from $495.00 to $525.00 and gave the company a “buy” rating in a research report on Monday, October 27th. JPMorgan Chase & Co. raised their price target on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a report on Monday, August 4th. Truist Financial raised their target price on HCA Healthcare from $460.00 to $495.00 and gave the company a “buy” rating in a report on Monday, October 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of HCA Healthcare in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $473.53.

HCA Healthcare Stock Up 1.1%

Shares of HCA stock opened at $476.33 on Monday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $478.88. The stock has a 50 day moving average of $427.73 and a 200-day moving average of $392.20. The firm has a market cap of $108.70 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 1.38 and a beta of 1.41.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $1.32. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The company had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. During the same period last year, the business posted $4.90 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s dividend payout ratio is presently 11.13%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.